Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

On October 21, 2024, the 2024 business EPS guidance was upgraded to growth of at least a low single-digit percentage at CER supported by the ...

We speak with Mohammed Charki, who knows a lot about partnerships between pharma and biotech, as he is currently “on loan” from Sanofi with start-up biotech Hemarina, where he is advising and ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

France considers blocking Sanofi's $16 billion consumer division sale to U.S. firm CD&R, citing concerns over healthcare ...